Delving into the Latest Updates on Cardiavent, Inc. with Synapse

Overview

Study Phase: Phase 1
Primary Objective:
• To evaluate the safety and tolerability of single ascending oral doses of CARD-024 in healthy subjects
Secondary Objectives:
To evaluate the pharmacokinetic (PK) profile of CARD-024 following ascending single oral doses of CARD-024
To evaluate the effect of CARD-024 on cardiovascular indices including plasma renin activity (PRA) and blood pressure (BP), biological markers of activity, following ascending single oral doses of CARD-024

Start Date01 Sep 2011

Sponsor / Collaborator

Cardiavent, Inc.

100 Clinical Results associated with Cardiavent, Inc.

Login to view more data

0 Patents (Medical) associated with Cardiavent, Inc.

Login to view more data

100 Deals associated with Cardiavent, Inc.

Login to view more data

100 Translational Medicine associated with Cardiavent, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data